Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options

by Zacks Equity Research Published on October 24,2018

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

• NKTR Quick QuoteNKTRNegative Net Change

• medical

The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis

by Zacks Equity Research Published on October 02,2018

The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis

• NKTR Quick QuoteNKTRNegative Net Change
• CSBR Quick QuoteCSBRNo Net Change
• CYDY Quick QuoteCYDYNegative Net Change
• INFI Quick QuoteINFIPositive Net Change
• ZTS Quick QuoteZTSNegative Net Change

5 Best Biotech Stocks to Buy In October

by Zacks Equity Research Published on October 01,2018

Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

• AGN Quick QuoteAGNPositive Net Change
• VKTX Quick QuoteVKTXNegative Net Change
• ACAD Quick QuoteACADNegative Net Change
• AMRN Quick QuoteAMRNNegative Net Change
• SRPT Quick QuoteSRPTNegative Net Change
• ALXN Quick QuoteALXNPositive Net Change
• GILD Quick QuoteGILDNegative Net Change
• INFI Quick QuoteINFIPositive Net Change
• CSBR Quick QuoteCSBRNo Net Change
• CYDY Quick QuoteCYDYNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• ZTS Quick QuoteZTSNegative Net Change
• MDGL Quick QuoteMDGLNegative Net Change

Lilly (LLY) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on September 10,2018

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

• LLY Quick QuoteLLYNegative Net Change
• VRTX Quick QuoteVRTXNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• FIXX Quick QuoteFIXXPositive Net Change

Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report?

by Zacks Equity Research Published on September 07,2018

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• NKTR Quick QuoteNKTRNegative Net Change

Endo (ENDP) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on September 05,2018

Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

• ENDP Quick QuoteENDPPositive Net Change
• LLY Quick QuoteLLYNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

5 Health Care ETFs Outperforming XLV on YTD Basis

by Zacks Equity Research Published on August 27,2018

Health care ETFs provide handsome returns year to date.

• PSCH Quick QuotePSCHNegative Net Change
• IHI Quick QuoteIHINegative Net Change
• FBT Quick QuoteFBTNegative Net Change
• XLV Quick QuoteXLVNegative Net Change
• IHF Quick QuoteIHFNegative Net Change
• XHE Quick QuoteXHENegative Net Change
• TNDM Quick QuoteTNDMNegative Net Change
• MDT Quick QuoteMDTNegative Net Change
• LGND Quick QuoteLGNDNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• UNH Quick QuoteUNHNegative Net Change

Is Nektar Therapeutics (NKTR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on August 24,2018

Is (NKTR) Outperforming Other Medical Stocks This Year?

• NKTR Quick QuoteNKTRNegative Net Change

High Beta, Momentum ETFs & Stocks to Trade in a Market Rally

by Sweta Killa Published on August 21,2018

While the rally seems to be broad-based, high beta and high momentum products are expected to lead the market.

• TRGP Quick QuoteTRGPNegative Net Change
• PEP Quick QuotePEPNegative Net Change
• RYAM Quick QuoteRYAMNegative Net Change
• MTUM Quick QuoteMTUMNegative Net Change
• SPHB Quick QuoteSPHBNegative Net Change
• ONEO Quick QuoteONEONegative Net Change
• PDP Quick QuotePDPNegative Net Change
• TSN Quick QuoteTSNPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• SODA Quick QuoteSODANo Net Change
• BPI Quick QuoteBPINo Net Change

Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y

by Zacks Equity Research Published on August 09,2018

Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.

• BMY Quick QuoteBMYNegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• SGEN Quick QuoteSGENPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Nektar Therapeutics (NKTR) Q2 Earnings Meet Estimates

by Zacks Equity Research Published on August 08,2018

Nektar (NKTR) delivered earnings and revenue surprises of 0.00% and 4.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

• NKTR Quick QuoteNKTRNegative Net Change

Why Nektar Therapeutics (NKTR) Might Surprise This Earnings Season

by Zacks Equity Research Published on August 07,2018

Nektar Therapeutics (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

• NKTR Quick QuoteNKTRNegative Net Change

Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?

by Zacks Equity Research Published on August 02,2018

Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.

• BMY Quick QuoteBMYNegative Net Change
• BDSI Quick QuoteBDSIPositive Net Change
• HZNP Quick QuoteHZNPPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook

by Zacks Equity Research Published on July 26,2018

Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales.

• BMY Quick QuoteBMYNegative Net Change
• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5%

by Zacks Equity Research Published on June 06,2018

Nektar Therapeutics (NKTR) shares rose nearly 7% in the last trading session, amid huge volumes.

• CCXI Quick QuoteCCXIPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Company News For Jun 5, 2018

by Zacks Equity Research Published on June 05,2018

Companies in the news are: GHDX,BAYN.DE, NKTR,DCPH

• GHDX Quick QuoteGHDXPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• DCPH Quick QuoteDCPHPositive Net Change

Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study

by Zacks Equity Research Published on June 05,2018

Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.

• RHHBY Quick QuoteRHHBYNegative Net Change
• BMY Quick QuoteBMYNegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?

by Zacks Equity Research Published on June 04,2018

Investors need to pay close attention to Nektar (NKTR) stock based on the movements in the options market lately.

• NKTR Quick QuoteNKTRNegative Net Change

Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

by Zacks Equity Research Published on June 01,2018

Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

• BMY Quick QuoteBMYNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change
• COLL Quick QuoteCOLLNegative Net Change
• TEVA Quick QuoteTEVANegative Net Change

Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y

by Zacks Equity Research Published on May 14,2018

Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.

• BMY Quick QuoteBMYNegative Net Change
• LLY Quick QuoteLLYNegative Net Change
• SHPG Quick QuoteSHPGNo Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

by Zacks Equity Research Published on April 26,2018

Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

• BMY Quick QuoteBMYNegative Net Change
• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?

by Sweta Killa Published on April 24,2018

Style Box ETF report for VIOG

• IWO Quick QuoteIWONegative Net Change
• VBK Quick QuoteVBKNegative Net Change
• CMD Quick QuoteCMDPositive Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Nektar Starts Phase I/II Combo for Advanced Solid Tumors

by Zacks Equity Research Published on April 12,2018

Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.

• RHHBY Quick QuoteRHHBYNegative Net Change
• BMY Quick QuoteBMYNegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y

by Zacks Equity Research Published on March 02,2018

Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.

• RHHBY Quick QuoteRHHBYNegative Net Change
• BMY Quick QuoteBMYNegative Net Change
• MRK Quick QuoteMRKNegative Net Change
• NKTR Quick QuoteNKTRNegative Net Change

Why Nektar (NKTR) Might Surprise This Earnings Season

by Zacks Equity Research Published on February 28,2018

Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

• NKTR Quick QuoteNKTRNegative Net Change